A Multicenter Randomized Double-Blind Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Ulcerative Colitis Who Have Failed Prior Biologic Therapy
Recruiting
99 years and younger
All
Phase
3
5 participants needed
1 Location
Brief description of study
The trial will enroll subjects who have had an inadequate response (IR) to prior biologic therapy (bio-IR).
The bio-IR population is defined as subjects with documented intolerance or inadequate response to one
or more of the approved biologics for UC (infliximab, adalimumab, golimumab, and/or vedolizumab).
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Ulcerative Colitis
-
Age: - 99 Years
-
Gender: All
Updated on
01 Aug 2024.
Study ID: 829968
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
A copy of the message has been sent to your email
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
